LYEL
Lyell Immunopharma, Inc.
$14.04
-0.01 (-0.07%)
At close · Jul 6
Market Cap
$327.61M
Shares
23,334,087
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.04
Open$14.11
Day$13.75–14.70
52W$9.03–45.00
Avg vol 30d202K
Short int1.3M · 5.6% float · 9.6d
Short vol62%
Last earningsMay 6, 2026
DataJun 2021–Jul 2026
Filing10-Q · May 6
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−32% below
−
Price vs 50-day avg
−14% below
◦
RSI (14)
50 · neutral
+
MACD trend
positive
−
52-week position
14% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $16 › 200d $21 — 200d above 50d
+
Institutional flow
+9% holders QoQ · +18 funds added
−
Insider flow
Net -$40.6K over 90 days · 100% sells
+
Short interest
5.64% of float · ▼ -2.7% MoM · 9.6 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
74 holders — near 1-yr high, broad support
Fundamentals
Fair
−
Revenue growth
−41% Y/Y
+
EPS growth
+39% Y/Y
−
Free cash flow
$-150.8M
+
Balance sheet
net cash $60.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−32% below
Bearish
Price vs 50-day avg
−14% below
Bearish
RSI (14)
50 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
14% · near low
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $16 › 200d $21 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +18 funds added
Insider flow
Distributing
Net -$40.6K over 90 days · 100% sells
Short interest
Falling
5.64% of float · ▼ -2.7% MoM · 9.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
74 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $9
Now $14 · 14%
52-wk high $45
vs 200-day avg -32%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and cash equivalents | $261M | first quarter ended March 31, 2026 | — |
| Cash | $247.2M | year ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LYEL
this stock
Lyell Immunopharma, Inc.
|
$327.61M | -54.4% | -41.0% | — | 5.6% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LYEL | +20.9% | +7.6% | -42.8% | -0.1% | -54.4% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +17.9% | +8.4% | -51.1% | -0.7% | -64.6% |